TrialAntimicrobial agents and chemotherapy2013

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.

Gabriel J Robbie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.